Skip to content

Trial Summary

A randomised phase II trial comparing the efficacy of single-dose or fractionated SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer (AZTEC)

Acronym:

AZTEC

ACTRN/NCT /ethics:

NCT03464942

Scientific title:

Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer

Sponsor / Cooperative group:

Peter MacCallum Cancer Centre, Australia

Trial & Patient Characteristics

Cancer TypeBreast
Trial TypeTreatment
PhasePhase II
Age Range18+ years
SexBoth
Tumour Stream Breast
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2018-08-01
Anticipated End Date2022-04-01

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorDr Hien Le
Recruitment StatusRecruiting